CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03575234
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:35.994291+00:00
Published At: 2019-08-28T00:00:00+00:00
Record Updated At: 2019-08-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma", "Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-08-28"
protocolSection.identificationModule.nctId: "NCT03575234"
protocolSection.identificationModule.officialTitle: "Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.